KRYS Krystal Biotech, Inc.

NASDAQ
$345.82

Krystal Biotech, Inc. (KRYS) is expected to report earnings on November 6, 2026, before the market open. The consensus earnings estimate is $1.91 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.8% since its last earnings release on August 3, 2026.

Krystal Biotech Beat Consensus Estimates
Monday, August 3, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 6
Friday · 7:00 AM ET
Earnings Whisper
-
vs $1.91
Rev est $126.5M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $339.18

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Krystal Biotech, Inc.

Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.